MML Investors Services
URGN icon

MML Investors Services’s UroGen Pharma URGN Stock Holding History

MML Investors Services’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$527K Sell
14,325
-6,477
-31% -$176K ﹤0.01% 2431
2026
Q1 		$374K Sell
20,802
-3,561
-15% -$71.4K ﹤0.01% 2415
2025
Q4 		$571K Buy
+24,363
New +$528K ﹤0.01% 2167

Other funds holding URGN

RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

MML Investors Services's URGN Position: Q2 2026 in Review

MML Investors Services reduced its UroGen Pharma (URGN) stake by 31% in Q2 2026, selling an estimated $176K and leaving 14,325 shares worth $527K. The position accounts for ﹤0.01% of the portfolio, ranked #2431.

MML Investors Services first reported a position in URGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $571K in Q4 2025. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • MML Investors Services held 14,325 shares of UroGen Pharma worth $527K as of Q2 2026.
  • MML Investors Services sold 6,477 UroGen Pharma shares in Q2 2026, an estimated $176K.
  • UroGen Pharma made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #2431 holding.
  • MML Investors Services first reported a position in UroGen Pharma in Q4 2025 and has held it in 3 quarters since.
  • MML Investors Services's UroGen Pharma position peaked at $571K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.